Welcome!

News Feed Item

Circassia's ToleroMune® Cat Allergy Treatment Maintains Symptom Improvement Two Years After Start of Short-Course Therapy

OXFORD, England and SAN ANTONIO, February 25, 2013 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune® cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.  The results were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, USA on Sunday 24 February.

The phase II study originally measured improvements in nasal and ocular allergy symptoms (Total Rhinoconjunctivitis Symptom Score; TRSS) in 202 patients, following treatment with ToleroMune® therapy or placebo.  Two years after the start of the study, and having received no further ToleroMune® treatment, 50 of the original patients returned to reassess their symptoms while exposed to cat allergens.  The results show that at the end of the cat allergen challenge, patients who had previously been treated with four doses of ToleroMune® therapy over 12 weeks had a significant improvement in symptoms two years later, compared with placebo (p<0.05; 50.0% TRSS improvement on ToleroMune® treatment vs 14.9% on placebo). These patients also maintained a substantial reduction in symptoms throughout their entire exposure to cat allergens over the four day challenge (38.3% TRSS improvement vs 13.4% on placebo).  In addition, the results show that these patients maintained consistent symptom improvements both 12 and 24 months after the start of treatment. The ToleroMune® therapy was well tolerated with a safety profile comparable to placebo.  

Commenting on the results, co-author of the AAAAI conference presentation, Professor Mark Larché, Canada Research Chair in Allergy and Immune Tolerance, McMaster University and St. Joseph's Healthcare, Hamilton, said, "Sustaining such a substantial improvement in patients' allergy symptoms two years after the start of the study is remarkable.  Achieving this with a short course of just four doses is even more impressive.  These results suggest that ToleroMune® therapy has the potential to revolutionise treatment for cat allergy patients."

"These excellent clinical results are extremely encouraging, and strongly support Circassia's decision to progress to phase III at the end of last year," said Steve Harris, Circassia's CEO.  "Offering patients sustained symptom control without the need for ongoing treatment is an important objective for allergy therapy.  In this study, our ToleroMune® treatment reduced symptoms by two and a half to three times the level achieved by several other allergy therapies in similar studies, and maintained the improvement over a significant period, demonstrating its potential to greatly improve the lives of patients around the world."

About cat allergy

Allergies are a significant global health issue.  Allergic rhinoconjunctivitis (ARC) affects up to 30% of adults and 40% of children in developed countries, and its prevalence is rising.  ARC reduces quality of life and impacts school and work attendance and performance.  In Continental Europe and the USA, cat allergy is one of the most common forms of the disease, and affects 10 - 15% of those with ARC and / or asthma.  As cat dander is widespread in the human environment, and widely found in public buildings, patients with cat allergy may experience significant symptoms despite attempting to avoid exposure.  Current treatment options include temporary symptom suppression with antihistamines, corticosteroids and cromones, or long-term whole allergen immunotherapy, which can require treatment for three to five years and has the potential to induce life-threatening anaphylactic reactions.  

About ToleroMune®

Circassia's cat allergy treatment is based on the company's novel, proprietary ToleroMune® technology.  This uses rationally-designed combinations of synthetic peptides to generate regulatory T cells to control allergic responses and induce immune tolerance.  Circassia's ToleroMune® cat allergy treatment consists of seven peptides identified from the major cat allergen Fel d 1.  It has successfully completed a number of phase II studies, which demonstrate that courses of short, simple treatment can substantially reduce patients' symptoms and have a favourable safety profile.  In long-term follow up, patients' symptoms remained greatly improved two years after the start of the study, despite no further treatment after the initial four doses given over 12 weeks.  Circassia's cat allergy treatment entered phase III clinical testing in October 2012.  

About Circassia

Circassia was founded by a team of highly experienced biotechnology scientists and entrepreneurs.  The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada.  Circassia's ToleroMune® technology was developed originally by scientists at Imperial College, London.  Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.

Contacts
Steve Harris
CEO
Circassia
Tel: +44(0)1865-784574
http://www.circassia.co.uk
Rob Budge
RJB Communications
Tel: +44(0)1865-760969
Mobile: +44(0)7710-741241


SOURCE Circassia

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Personalization has long been the holy grail of marketing. Simply stated, communicate the most relevant offer to the right person and you will increase sales. To achieve this, you must understand the individual. Consequently, digital marketers developed many ways to gather and leverage customer information to deliver targeted experiences. In his session at @ThingsExpo, Lou Casal, Founder and Principal Consultant at Practicala, discussed how the Internet of Things (IoT) has accelerated our abil...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
SYS-CON Events announced today Telecom Reseller has been named “Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Telecom Reseller reports on Unified Communications, UCaaS, BPaaS for enterprise and SMBs. They report extensively on both customer premises based solutions such as IP-PBX as well as cloud based and hosted platforms.
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...